Cuproplasia and cuproptosis, two sides of the coin
Cancer Communications · 2025-05 · 45 (5) · 505-524
DOI: 10.1002/cac2.70001 ↗At a glance
Übersichtsarbeit in Cancer Communications, published online on 2025-01-25. Written by Kaizhong Lu and 4 co-authors. Institution: Department of Medical Oncology, Zhejiang Key Laboratory of Multi-omics Precision Diagnosis and Treatment of Liver Diseases, Cancer Center of Zhejiang…. Major MEDLINE topics: Copper, Neoplasms. Cited 52 times so far (Crossref); 148 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Natural Science Foundation of Zhejiang Province.
Abstract (original language)
Copper is an essential micronutrient in the human body, mainly acting as a crucial cofactor required for a wide range of physiological processes across nearly all cell types. Recent advances revealed that tumor cells seize copper to fulfill their rapid proliferation, metastasis, immune evasion, and so on by reprogramming the copper regulatory network, defined as cuproplasia. Thus, targeting copper chelation to reduce copper levels has been considered a rational tumor therapy strategy. However, overloaded copper ions could be toxic, which leads to the aggregation of lipoylated mitochondrial proteins and the depletion of iron‐sulfur clusters, ultimately resulting in cell death, termed cuproptosis. Upon its discovery, cuproptosis has attracted great interest from oncologists, and targeting cuproptosis by copper ionophores exhibits as a potential anti‐tumor therapy. In this review, we present the underlying mechanisms involved in cuproplasia and cuproptosis. Additionally, we sum up the chemicals targeting either cuproplasia or cuproptosis for cancer therapy. Further attention should be paid to distinguishing cancer patients who are suitable for targeting cuproplasia or cuproptosis.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Medical Oncology, Zhejiang Key Laboratory of Multi-omics Precision Diagnosis and Treatment of Liver Diseases, Cancer Center of Zhejiang University, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang U…
- Department of Oncology, The Second Affiliated Hospital of Zhejiang Chinese Medical University, Xinhua Hospital of Zhejiang Province, Hangzhou, Zhejiang, P. R. China.
- Key Laboratory for Research on the Pathogenesis of Inflammation-Cancer Transformation in Intestinal Diseases, Zhejiang Engineering Research Center of Intelligent Equipment of Chronic Chinese and Western Medicine, Hangzh…
ORCID profiles: Kaizhong Lu, Lifeng Feng
Funding
- Natural Science Foundation of Zhejiang Province
Cite
APA
Lu, K., Wijaya, C. S., Yao, Q., Jin, H., & Feng, L. (2025). Cuproplasia and cuproptosis, two sides of the coin. Cancer Communications, 45(5), 505-524. https://doi.org/10.1002/cac2.70001
Vancouver
Lu K, Wijaya CS, Yao Q, Jin H, Feng L. Cuproplasia and cuproptosis, two sides of the coin. Cancer Communications. 2025;45(5):505-524. doi:10.1002/cac2.70001
BibTeX
@article{Lu2025,
author = {Lu, Kaizhong and Wijaya, Chandra Sugiarto and Yao, Qinghua and Jin, Hongchuan and Feng, Lifeng},
title = {Cuproplasia and cuproptosis, two sides of the coin},
journal = {Cancer Communications},
year = {2025},
volume = {45},
number = {5},
pages = {505--524},
doi = {10.1002/cac2.70001}
}
EUVIMED